Litchfield Hills Initiates Coverage On Silexion Therapeutics with Buy Rating, Announces Price Target of $6

Benzinga · 1d ago
Litchfield Hills analyst Theodore O'Neill initiates coverage on Silexion Therapeutics (NASDAQ:SLXN) with a Buy rating and announces Price Target of $6.